Press ReleaseCovis Announces Successful Completion of Its Previously Announced Financial Recapitalization Transaction, Resulting in a Material Strengthening of Its Financial Position – Transaction supported by 100% of First Lien and 100% of Second Lien Lenders –...
Search results:
Covis Statement on FDA Decision to Withdraw Approval of Makena®
Press ReleaseCovis Statement on FDA Decision to Withdraw Approval of Makena®Zug, Switzerland, April 7, 2023 – Following the U.S. Food and Drug Administration's decision, Covis Pharma Group ("Covis") is effectuating the withdrawal of Makena® (hydroxyprogesterone...
Covis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors, Leading to a Material Strengthening of Its Financial Position, Including the Elimination of ~$450 Million of Debt
Press ReleaseCovis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors,Leading to a Material Strengthening of Its Financial Position,Including the Elimination of ~$450 Million of Debt - Support Agreement signed by approximately 95% of First...
2023
News release 2023
Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing
Press ReleaseCovis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing – Company Has Requested an Orderly Wind-down in Effort to Voluntarily Withdraw Makena®Zug, Switzerland, March 07, 2023 – Covis Pharma Group (“Covis”), today...
Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD
Press ReleaseCovis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPDZug, Switzerland, October 25, 2022 – Covis Pharma Group ("Covis"), a global specialty...
Covis Pharma Reports on FDA Advisory Committee Hearing for Makena®
Press ReleaseCovis Pharma Reports on FDA Advisory Committee Hearing for Makena® Zug, Switzerland, 19 October 2022 – Covis Pharma Group (the “Company”), today reported that the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee to the U.S. Food and Drug...
Lanoxin WAC
LANOXIN® (digoxin) InjectionInformation for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about WAC of these drugs is being provided to Colorado...
Tudorza WAC
TUDORZA® PRESSAIR® (aclidinium bromide inhalation power)Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about WAC of these drugs is...
Feraheme WAC
FERAHEME® (ferumoxytol injection)Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about WAC of these drugs is being provided to...
Prilosec WAC
PRILOSEC® (omeprazole magnesium) for Delayed-Release Oral SuspensionInformation for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about WAC of...
Duaklir WAC
DUAKLIR® PRESSAIR®(aclidinium bromide and formoterol fumarate inhalation powder)Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about...
Alvesco WAC
ALVESCO® (ciclesonide) Inhalation AerosolInformation for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131The prices listed below are Wholesaler Acquisition Costs (WAC). Information about WAC of these drugs is being provided...
Covis Pharma Group Announces Executive Leadership Appointment in Canada
Press ReleaseCovis Pharma Group Announces Executive Leadership Appointment in CanadaZug, Switzerland, 14 July 2022 – Covis Pharma Group (the "Company"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening...
Feraheme ISI
Feraheme® ISI (ferumoxytol injection)Feraheme Important Safety InformationWARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial...
Covis Pharma Provides Update on FDA Public Hearing for Makena®
Press ReleaseCovis Pharma Provides Update on FDA Public Hearing for Makena®Zug, Switzerland, June 14, 2022 – Covis Pharma GmbH, an affiliate of Group S.à r.l. (collectively, “Covis”), announced today that the U.S. Food & Drug Administration (FDA) anticipates...
Development
Product DevelopmentToo many patients and families continue to experience the effects of serious health conditions that have no available treatments or cures. Covis seeks to collaborate on and acquire promising therapies at various stages of development, and advance...
ISR Concept Form
ISR Concept FormCOVIS INVESTIGATOR SPONSORED RESEARCH CONCEPT FORM Covis Pharma is committed to advancing science by supporting external independent research activities.Specific areas of interest related to respiratory diseases (Asthma & COPD): Current treatment...
Medical Affairs
Medical InformationUnited StatesAdverse Events or Product Complaints To report suspected adverse events or product complaints in the United States, please call 1-877-411-2510 (option #1) or email [email protected] (option #2). You may also report suspected...
Educational Grant Application
Educational Grant ApplicationEDUCATIONAL GRANT REQUEST FORMACCREDITED AND NON-ACCREDITED EDUCATIONAL ACTIVITIES (FORMULAIRE DE DEMANDE DE SUBVENTION À DES FINS ÉDUCATIVES (ACTIVITÉS ACCRÉDITÉES ET NON ACCRÉDITÉES) )Grant requests should be submitted to Covis at least...
2013
News release 2013
2015
News release 2015
2017
News release 2017
2018
News release 2018
2021
News release 2021